CLDI · Calidi Biotherapeutics, Inc.
$0.09
-0.01 (-12.80%)
At close · Jul 29
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed May 14, 2026
Market Cap
$1.80M
Shares
19.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.11
Open$0.11
Day$0.10–0.11
52W$0.10–10.92
Avg vol 30d6.8M
Short int3.4M · 17.7% float · 1.6d
Short vol15%
Last earningsSep 11, 2024
DataNov 2021–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−85%
below
Price vs 50-day avg
−31%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−34%
trailing
6-month return
−89%
trailing
YTD return
−91%
this year
Relative strength
−97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
7 of 28 funds reported for Jun 30 · net +42.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.72% of float · ▼ -20.0% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Squeeze score
49
elevated · 0–100
Fundamentals
EPS growth
+83%
Y/Y
Balance sheet
$9.0M
net cash
Quant / Vol
risk profile
Volatility
108%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
13.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−85%
Bearish
Price vs 50-day avg
−31%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
7 of 28 funds reported for Jun 30 · net +42.3K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
17.72% of float · ▼ -20.0% MoM · 1.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $11
vs 200-day avg -85%
vs 50-day avg -31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDI
this stock
Calidi Biotherapeutics, Inc.
|
$1.80M | -90.9% | — | — | 17.7% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDI | +7.0% | -33.5% | -89.1% | -37.1% | -90.9% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | +8.0% | -33.5% | -96.6% | -36.3% | -99.5% |